

ONLINE ONLY

## Supplemental material

**Characterization of patient-derived bone marrow human mesenchymal stem cells as oncolytic virus carriers for the treatment of glioblastoma**

Shimizu et al.

<https://thejns.org/doi/abs/10.3171/2021.3.JNS203045>

**DISCLAIMER** The *Journal of Neurosurgery* acknowledges that the following section is published verbatim as submitted by the authors and did not go through either the *Journal's* peer-review or editing process.

**Supplementary Figure 1.** Flow chart of patient derived BM-hMSCs. PD-BM-MSCs were infected with Ad/F35-CMV-GFP to determine the localization to tumor. PD-BM-MSC-001 and PD-BM-MSC-004 were infected Delta-24-RGD for survival analysis.

**Supplementary Figure 2.** Time schedule for survival analysis. **A**, Intratumoral injections of Delta-24-RGD were given 4 and 8 days after tumor implantation. **B**, PD-BM-hMSCs were thawed and cultured for 7 days prior to tumor implantation. Intracarotid injections of PD-BM-MSC-D24 were given 4 and 18 days after tumor implantation.

**Supplementary Figure 3.** Bioluminescence imaging over the time course in Experiment 2 revealed marked differences in photon flux among the groups by 4 weeks. Individual mice were tracked and imaged weekly.





